Safety and Efficacy of HexaBody ‐ DR5 / DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70546 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Marije B Overdijk und 19 weiteren Autor:innen. Beteiligte Einrichtung: Genmab B.V., Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Chemical and Drug Induced Liver Injury, Neoplasms, Receptors, TNF-Related Apoptosis-Inducing Ligand. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
HexaBody‐DR5/DR5 (GEN1029) is a death receptor 5 (DR5) agonist composed of two humanized immunoglobulin G1 (IgG1) antibodies, Hx‐DR5‐01 and Hx‐DR5‐05, that bind non‐overlapping DR5 epitopes with nanomolar affinity. HexaBody‐DR5/DR5 is designed to activate the TRAIL pathway through DR5 clustering. This phase 1/2a, open‐label, multi‐center study aimed to determine the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of HexaBody‐DR5/DR5 in patients with advanced solid tumors. In the study, 46 patients received biweekly intravenous injections of HexaBody‐DR5/DR5 at doses ranging from 0.1 to 3.0 mg/kg, including patients with colorectal, gastric, non‐small‐cell lung, pancreatic, and triple‐negative breast cancer. Safety evaluations revealed that 76.1% of patients experienced at least one grade (G) ≥ 3 treatment‐emergent adverse event (TEAE), and 45.7% had drug‐related G ≥ 3 events. The most frequent G ≥ 3 drug‐related TEAEs were elevations of liver transaminases and diarrhea. According to RECIST criteria, 32.6% of patients showed stable disease. No patients achieved a partial or complete response. Exploratory assessments of cleaved cytokeratin 18 (cCK18) plasma levels indicated apoptotic pathway activation upon treatment. Reductions in circulating tumor DNA (ctDNA) levels and tumor metabolic activity according to PERCIST criteria suggested tumor‐targeted biological activity. Nonclinical studies in vitro using human liver models demonstrated that HexaBody‐DR5/DR5 directly inhibits viability of hepatocytes, but not Kupffer cells. The non‐clinical liver toxicity was driven by dual epitope binding and hexamerization features, independent of FcγR‐mediated crosslinking. Overall, these findings suggest that the TRAIL pathway has potential as a target for cancer therapy, provided tumor‐specificity is sufficiently high to achieve an acceptable therapeutic index.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genmab B.V., Utrecht, the Netherlands.
- Newcastle University Translational and Clinical Research Institute, Medical School, Newcastle University, Newcastle upon Tyne, UK.
- Yale Cancer Center, Yale University, New Haven, Connecticut, USA.
- Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Institute of Cancer Research and the Royal Marsden, London, UK.
- Early Drug Development Unit, Vall d'Hebron Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
ORCID-Profile: Marije B Overdijk, Kristin Strumane, Ruth Plummer, Patricia LoRusso, Jordi Rodon Ahnert, Udai Banerji, Elena Garralda, Emiliano Calvo, Naomi Hoevenaars, Sieto Bosgra, Panagiota Diamantopoulou Reiter, Maria Jure-Kunkel
Zitieren
APA
Overdijk, M. B., Strumane, K., Plummer, R., LoRusso, P., Rodon Ahnert, J., Banerji, U., Garralda, E., Calvo, E., Si, H., Hoevenaars, N., Mortensen, J. T., Bosgra, S., Malmberg, A., Ellekilde-Pedersen, M., Ramirez-Andersen, T., Diamantopoulou Reiter, P., Favaro, E., Forssmann, U., Breij, E. C. W., & Jure-Kunkel, M. (2026). Safety and Efficacy of HexaBody ‐ DR5 / DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity. Clinical and Translational Science. https://doi.org/10.1111/cts.70546
Vancouver
Overdijk MB, Strumane K, Plummer R, LoRusso P, Rodon Ahnert J, Banerji U, et al. Safety and Efficacy of HexaBody ‐ DR5 / DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity. Clinical and Translational Science. 2026. doi:10.1111/cts.70546
BibTeX
@article{Overdijk2026,
author = {Overdijk, Marije B and Strumane, Kristin and Plummer, Ruth and LoRusso, Patricia and Rodon Ahnert, Jordi and Banerji, Udai and Garralda, Elena and Calvo, Emiliano and Si, Han and Hoevenaars, Naomi and Mortensen, Jens Thing and Bosgra, Sieto and Malmberg, Anders and Ellekilde-Pedersen, Merete and Ramirez-Andersen, Teresa and Diamantopoulou Reiter, Panagiota and Favaro, Elena and Forssmann, Ulf and Breij, Esther C W and Jure-Kunkel, Maria},
title = {Safety and Efficacy of HexaBody ‐ DR5 / DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70546}
}
EUVIMED